-
1 Comment
From a valuation standpoint, the stock is 92.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 2573.2.
Based on the above factors, Seer, Inc gets an overall score of 0/5.
Sector | Healthcare |
---|---|
Industry | Biotechnology |
ISIN | US81578P1066 |
Exchange | NASDAQ |
CurrencyCode | USD |
Market Cap | 109M |
---|---|
PE Ratio | None |
Target Price | 3 |
Beta | 1.58 |
Dividend Yield | None |
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for SEER using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025